Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database

A real-world pharmacovigilance study using the FAERS database investigated the safety concerns of glucagon-like peptide 1 receptor agonists (GLP1-RAs) related to suicide, hair loss, and aspiration. The study found no positive signals for these adverse events with GLP1-RAs, although they showed higher reporting rates compared to other antidiabetic medications. Specifically, semaglutide and liraglutide had higher suicidal event reports, and GLP1-RAs were the most reported class for hair loss. Despite not meeting the criteria for positive signals, the findings suggest the need for continued monitoring and reporting of these events.